While intraparenchymal injection of anti-EpCAM CAR-T cells reduced LL/2 tumor growth in the brain in vivo, intravenous administration of the CAR-T cells failed to accumulate within the tumor and, in both cases, failed to persist within the tumor, suggesting that the success of CAR-T cells may be cancer- and location-specific [105]. The gene discussed is EPCAM; the disease is cancer.